Scilex Explores Strategic Options, Analyst Initiates On Blockbuster Potential For Sciatica Pain Candidate
Scilex Explores Strategic Options, Analyst Initiates On Blockbuster Potential For Sciatica Pain Candidate
The company has three FDA-approved products:Alliance Global Partners initiated coverage on Scilex Holding Company (NASDAQ:SCLX), a company focused on non-opioid pain treatment solutions.
全球合作伙伴公司初始對Scilex Holding Company (NASDAQ:SCLX) 進行了覆蓋，這是一家專注於非阿片類疼痛治療解決方案的公司。
On Wednesday, Scilex announced that its board of directors authorized management to explore strategic options, including a potential spinoff or dividend distribution the common stock
週三，Scilex宣佈其董事會授權管理層探討戰略選擇，包括潛在的剝離或派息普通股。
The board is also considering a public listing of Scilex Pharma's securities on exchanges outside the U.S., such as in Hong Kong, or other strategic transactions.
董事會同時考慮將Scilex Pharma證券在美國以外的交易所進行公開上市，比如在香港，或者其他戰略性交易。
The company has three FDA-approved products:
該公司有三個FDA批准的產品：
- Lead drug product ZTlido, a 1.8% lidocaine topical product targeting neuropathic pain associated with postherpetic neuralgia or shingles pain.
- Elyxyb (celecoxib oral solution) for the acute treatment of migraine.
- Gloperba (colchicine USP) for painful gout flares in adults.
- 主導藥物產品ZTlido，一種目標是神經病理性疼痛（如帶狀皰疹後神經痛或帶狀皰疹疼痛）的1.8%利多卡因局部產品。
- Elyxyb（依來昔布口服溶液），用於急性偏頭痛治療。
- Gloperba（秋水仙鹼USP），用於治療成人痛風發作。
Scilex's Phase 3 candidate, SEMDEXA (SP-102), a non-opioid injectable corticosteroid gel designed to treat lumbosacral radicular pain, commonly known as sciatica.
Scilex的第三階段候選藥物SEMDXA（SP-102），一種非阿片類可注射的皮質類固醇凝膠，旨在治療腰骶神經根痛，俗稱坐骨神經痛。
The current treatment involves off-label use of epidural steroid injections, administered more than 12 million times a year.
目前的治療方案涉及使用硬膜外腎上腺皮質類固醇注射劑的劑量，每年超過1200萬次。
If approved, SEMDEXA can become the standard treatment for sciatica. At its peak, it could reach blockbuster status and generate over $1 billion in annual sales.
如果獲批，SEMDEXA可以成爲坐骨神經痛的標準治療方法。在巔峯時期，它有可能達到暴利地位，並創造超過10億美元的年銷售額。
Scilex is set to begin a Phase 3 safety trial for SEMDEXA in the fourth quarter of 2024. A possible FDA marketing application submission is planned for 2026. If approved, the product could launch in 2027.
Scilex計劃在2024年第四季度開始進行SEMDEXA的第3階段安全試驗。可能會在2026年提交FDA的營銷申請。如果獲批，該產品可能會在2027年上市。
The analyst anticipates that SEMDEXA, once on the market, could generate $1.2 billion in sales by 2030.
分析師預計，一旦SEMDEXA上市，到2030年其銷售額可能達到12億美元。
Alliance initiates Scilex Holding with a Buy rating and a price target of $14.
Alliance以買入評級和14美元的目標價啓動Scilex Holding。
In July, Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company and Denali Capital Acquisition Corp. (NASDAQ:DECA), a special purpose acquisition company, signed a letter of intent for a proposed business combination.
7月，Scilex Holding Company的全資子公司Semnur Pharmaceuticals Inc.與特殊目的收購公司Denali Capital Acquisition Corp.（納斯達克：DECA）簽署了一份擬議業務合併的意向書。
Price Action: Scilex stock is up 6.5% at 86 cents at last check Wednesday.
股價走勢：上週三最後一次交易時，Scilex股價上漲6.5%，報0.86美元。
- Citigroup Remains A Compelling Investment Opportunity: Analysts Take On Q3 Performance
- 花旗集團仍然是一個令人信服的投資機會：分析師對第三季度業績的看法
譯文內容由第三人軟體翻譯。
